Comparison of Acute Kidney Injury During Treatment with Vancomycin in Combination with Piperacillin-Tazobactam or Cefepime
Comparison of Acute Kidney Injury During Treatment with Vancomycin in Combination with Piperacillin-Tazobactam or Cefepime
复制标题
DOI：
10.1002/phar.1428
复制
发表时间：
2014-07-01
期刊：
影响因子：
4.1
通讯作者：
Jankowski, Christopher A.
中科院分区：
文献类型：
--
作者：
Gomes, Diane M.;Smotherman, Carmen;Jankowski, Christopher A.
研究目的评估观察到的急性肾损伤（阿基）的发生率在成人患者接受哌拉西林-他唑巴坦和万古霉素或头孢吡肟-万古霉素超过48小时。设计回顾性匹配队列。设置大型学术医疗中心。患者没有预先存在的肾功能不全的成人患者入院超过8个月的时间内接受哌拉西林-他唑巴坦和万古霉素或头孢吡肟-万古霉素的组合。评价万古霉素治疗超过48小时的阿基，AKI由急性肾损伤网络标准定义。测量和主要结果总共评价了224名接受任一抗微生物组合的患者的阿基。在非匹配分析中，哌拉西林-他唑巴坦和万古霉素组的阿基发生率（34.8%）显著高于头孢吡肟-万古霉素组（12.5%）（p
STUDY OBJECTIVE To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours.DESIGN Retrospective matched cohort.SETTING Large academic medical center.PATIENTS Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria.MEASUREMENTS AND MAIN RESULTS A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin-tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p